R Squared’s Pliant Therapeutics PLRX Stock Holding History

R Squared’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,490	Closed	-$32.8K	–	1178
2024 Q4	$32.8K	Buy	+2,490	New	+$34K	0.03%	668

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

R Squared's PLRX Position: Q1 2025 in Review

R Squared sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 2,490 shares — an estimated $32.8K sold.

R Squared first reported a position in PLRX in Q4 2024 and held it in 1 quarter. The position peaked at $32.8K in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

R Squared reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,490 Pliant Therapeutics shares in Q1 2025, an estimated $32.8K.
R Squared first reported a position in Pliant Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Pliant Therapeutics position peaked at $32.8K in Q4 2024.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.